Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

R2 and Hologic get US OK CAD (computer-aided detection)/FFDM (full field digital mammography) combination:

This article was originally published in Clinica

  • News

Executive Summary

R2 Technology has received US FDA approval to use its ImageChecker computer-aided detection (CAD) system with Hologic's full field digital mammography (FFDM) system, Selenia. R2's product provides radiologists with "a second pair of eyes" when reading mammograms, improving the chance of detecting findings that might otherwise be overlooked. Hologic believes that over a half of all Selenia FFDM systems sold will be equipped with CAD technology. The Bedford, Massachusetts-based firm has exclusive worldwide distribution rights to sell the R2 customised product in combination with its Selenia system. It also has distribution rights for R2 CAD products for use with conventional film-based mammography systems that can be upgraded to digital mammography systems.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

See All
UsernamePublicRestriction

Register

MT058372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By